Kornimate/medical-research-clean huggingface dataset:
comparison of the effects of vojta and bobath treatment on gait and balance in diplegic cerebral palsy

Conditions: Cerebral Palsy Spastic Diplegia

Summary: this study aims compare the effects of vojta verses bobath therapy on gait in children with diplegic cerebral palsy and to compare the effects of vojta versus bobath therapy on balance in children with diplegic cerebral palsy. the study will also determine the combined effects of vojta and bobath on gait and balance in children with diplegic cerebral palsy.

the study may provide non-invasive and cost-effective treatment option in improving balance \& gait in children with cerebral palsy. this can increase the child independence, confidence and quality of life. additionally, this study may contribute to the development of evidence-based rehabilitation protocols, which can help guide clinical decision-making and treatment options. the study may provide insight into the feasibility and safety of combining vojta and bobath treatments, which can guide future research and practice in this area. moreover, combination of treatments may have better outcomes as compared to the two individual techniques. the study aims compare the effects of vojta verses bobath therapy on gait in children with diplegic cerebral palsy and to compare the effects of vojta versus bobath therapy on balance in children with diplegic cerebral palsy. the study will also determine the combined effects of vojta and bobath on gait and balance in children with diplegic cerebral palsy.

Eligibility criteria:
inclusion criteria: * diagnosed cases of spastic diplegic cerebral palsy * gmfcs level ii \& iii * modified ashworth score greater than 1+ * age 3-8 years * either gender * children capable of understanding and executing commands; * children who can adopt the orthostatic position necessary to assess balance \& gait exclusion criteria: * children with any other associated disease (ddh, any orthopedic complication) * children with mental retardation; * who cannot participate constantly in physical therapy sessions; * profound visual or hearing impairments;

Keywords: cerebral palsy bobath therapy vojta therapy balance gait
combination antimalarials in uncomplicated malaria

Conditions: Malaria

Summary: the purpose of this study is to study the efficacy of sulfadoxine-pyrimethamine on its own and compare this with efficacy of a new combination antimalarial therapy, either sulphadoxine-pyrimethamine plus artesunate or artemether-lumefantrine.

the resistance of plasmodium falciparum to anti-malarial drugs is a serious impediment to the control of malaria. in the south east african combination anti-malarial therapy (seacat) evaluation, there will be a comprehensive evaluation of phased introduction of combination anti-malarials (cat) in mozambique, swaziland and south africa. in order to facilitate formulation of an effective regional drug policy and provide a database for decision-making on the implementation of combination therapy, it is essential that the in vivo response to cat in all three countries be investigated. an sp therapeutic efficacy study will be conducted according to this modified world health organization (who) protocol to guide the selection of cat. after cat is introduced an in vivo cat efficacy study will then be conducted to evaluate the efficacy of artesunate plus sp (or artemether-lumefantrine in kwazulu natal and limpopo). in areas of low intensity malaria transmission the cat in vivo study results will be compared across sites and with those found at baseline with monotherapy, for each site.

Eligibility criteria:
inclusion criteria: * male or female, older than 12 months. * weight \> 10 kg. * diagnoses of uncomplicated acute p. falciparum malaria parasitaemia of up to 250 000 asexual parasite/mcl blood with axillary temperature of greater than and equal to 37.5 or history of fever * documented informed consent * lives close enough to the health centre for reliable follow up exclusion criteria: * has received anti-malarial treatment in the past 7 days. * severely ill (based on who criteria for severe malaria ) or if patient is considered, in the opinion of the investigator or designee, to have moderately severe malaria (e.g. prostrate, repeated vomiting, dehydrated). * has received cotrimoxazole or chloramphenicol in the past 7 days. * history of glucose-6-phosphate dehydrogenase (g6pd) deficiency (not a contra-indication for artemether-lumefantrine). * is pregnant or breastfeeding. * has a history of allergy to any of the study drugs (including other sulphonamides e.g. cotrimoxazole, other artemisinin derivatives e.g. artemether-lumefantrine).

Keywords: malaria efficacy pharmacokinetic gametocyte molecular markers sulfadoxine-pyrimethamine artesunate artemisinin
rapid evaluation of amantadine for treatment of cocaine abuse/dependence - 4

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to empirically test a series of medications to: 1) determine each medication's efficacy in treatment of cocaine abuse/dependence; 2) find most effective dose range for each medication. in this study, amantadine is tested."

16-week participation plus a 2 weekk lead-in period. participants are assigned randomly to placebo or amantadine. participants attend group meeting 3 times/week

Eligibility criteria:
inclusion criteria: m/f, ages 18-65. cocaine dependence according to dms-iv criteria. self-reported use within the last 30 days. agreeable to conditions of the study and signed informed consent. exclusion criteria: psychiatric disorder that requires medication therapy, history of seizures. pregnant and/or nursing women. dependence on etoh or benzodiazepines or other sedative-hypnotics. acute hepatitis. other medical conditions that deem participation to be unsafe.

Keywords: amantadine cocaine pharmacotherapy outpatient
convenience, tolerability, and safety of change in the administration of rivastigmine from capsules to a transdermal patch in patients with mild to moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: this study used two doses of rivastigmine transdermal patch (5 cm\^2, 10 cm\^2) to establish the feasibility of 2 switch schedules (with transdermal patch one-step dose titration or without dose titration) from rivastigmine capsules (3 mg bid (bis in die, twice a day), 4,5 mg bid, 6 mg bid) to rivastigmine transdermal patch and to assess safety, tolerability, convenience, and caregivers preferences of rivastigmine transdermal patch versus capsules.


Eligibility criteria:
inclusion criteria: * meet dsm-iv (diagnostic \& statistical manual of mental disorders, version iv) criteria for dementia of alzheimer type and nincds-adrda (national institute of neurological and communicative disorders and stroke and the alzheimer's disease and related disorders association) criteria for probable alzheimer's disease (ad), have a mmse (mini mental state examination) score \> 10 and \< 26 * have received continuous treatment with rivastigmine capsules at least with 3 mg bid (6 mg of total daily dose) for at least 3 months before entering in the study * cooperative, willing to complete all aspects of the study, and capable of doing so, either alone or with the aid of a responsible caregiver * have a primary caregiver willing to accept responsibility for supervising the treatment, (eg, application and removal of the patch daily at approximately the same time of day) and assessing the condition of the patient throughout the study. exclusion criteria: * a medical or neurological condition other that ad that could explain the patients dementia (eg, huntington's disease, parkinson's disease, abnormal thyroid function test, b12 or folate deficiency, post-traumatic conditions, syphilis) * current diagnosis of an active skin lesion/disorder that would prevent accurate assessment of the adhesion and potential skin irritation of the patch (e.g., atopic dermatitis, wounded or scratched skin in the area of the patch application) * history of allergy to topical products containing vitamin e * taken any of the following substances prior to randomization: * succinylcholine-type muscle relaxants during the previous 2 weeks * an investigational drug during the previous 4 weeks other protocol-defined inclusion/exclusion criteria applied to the study.

Keywords: alzheimer's rivastigmine transdermal safety randomized switch patch
safety, tolerability, pk and pd of lgt209 in healthy volunteers and patients with hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: this study is designed to measure the effects of lgt209 when given intravenously to patients with high cholesterol who are on stable doses of statin medications, and to healthy subjects with elevated cholesterol


Eligibility criteria:
inclusion criteria: * healthy volunteers: male and female subjects 18 to 70 years of age, in general good health but with high cholesterol * statin patients: male and female patients 18 to 70 years of age, with high cholesterol on stable statin therapy for at least 3 months exclusion criteria: * healthy volunteers: history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes * women of child-bearing potential unless using highly effective methods of contraception * statin patients: use of any prescription drugs for lipid lowering other than hmg co-a reductase inhibitors (statins); use of two concurrent antihypertensive medications is allowed, provided stable dosing has been achieved for the prior 3 months * women of child-bearing potential unless using highly effective methods of contraception other protocol-defined inclusion/exclusion criteria may apply

Keywords: hypercholesterolemia, lgt209, pcsk9, ldl-c
home non invasive ventilation for copd patients

Conditions: Chronic Obstructive Pulmonary Disease; Hypercapnic Respiratory Failure

Summary: chronic obstructive pulmonary disease (copd) patients are more likely to develop acute hypercapnic respiratory failure. in the acute phase, non invasive ventilation has been shown to improve mortality and reduce intubation rate. few studies are available about long term benefits of home non invasive ventilation in copd patients with chronic hypercapnic respiratory failure who survived after an acute episode. the purpose of this study is to determine whether home non invasive ventilation can reduce recurrent acute hypercapnic respiratory failure in copd patients who survived an acute hypercapnic respiratory failure episode treated by non invasive ventilation.


Eligibility criteria:
inclusion criteria: * copd patients who survived after an acute episode of hypercapnic respiratory failure * patients weaned from ventilation ( non invasive ventilation or mechanical ventilation) prescribed for acute episode since at least five days with following arterial blood gas : ph \> 7.35 and pco2 \> = 45 mmhg exclusion criteria: * severe obstructive sleep apnea ( di \> 30/h) * non copd cause of respiratory failure * serious comorbidity * adverse psychological status
preliminary efficacy analysis of "c" single flap plasty reconstruction after laparoscopic proximal gastrectomy

Conditions: Gastric Cancer; Reflux Esophagitis

Summary: the incidence of proximal gastric cancer has increased significantly in recent years. this may be due to weight gain, alcohol consumption, gastroesophageal reflux disease (gerd), and precancerous lesions. with a deeper understanding of the pattern of lymph node metastasis and the emergence of anti-reflux procedures, proximal gastrectomy has gradually received clinical attention. for early-stage upper gastric cancer and esophagogastric combination cancer cases that are expected to have a good prognosis, the ideal surgical procedure should be to preserve the distal stomach to improve the quality of life and to choose a reasonable digestive tract reconstruction method to prevent reflux. the anti-reflux effect of various proximal gastrectomy digestive tract reconstruction methods and the advantages and disadvantages of various surgical procedures are controversial, and the recognized ideal reconstruction method has not yet been established. therefore, we propose a reconstruction called the "c" single flap plasty reconstruction. this study aimed to investigate the efficacy and safety of proximal gastrectomy combined with "c" single flap plasty reconstruction in the treatment of gastric cancer.


Eligibility criteria:
inclusion criteria: 1. age between 18-80 years old, male or female; 2. pathological diagnosis of preoperative endoscopic biopsy: the tumor is located in the upper 1/3 of the stomach (including the esophagogastric junction), and the clinical staging of gastric cancer： ia and ib (t1n0m0, t1n1m0, and t2n0m0) according to the eighth edition of the ajcc ; 3. no distant metastasis was observed on preoperative chest radiograph, abdominal ultrasound, or upper abdominal ct; 4. asa grade 1-3; 5. patients without contraindications to surgery; 6. patients and their families voluntarily signed the informed consent form and participated in the study; exclusion criteria: 1. patients diagnosed with primary tumors or distant metastasis; 2. patients whose tumor is located in the greater curvature side of the stomach; 3. patients with coagulation dysfunction that could not be corrected; 4. patients who were diagnosed with viral hepatitis and cirrhosis; 5. patients who were diagnosed with diabetes mellitus, uncontrolled or controlled with insulin; 6. patients with organ failure such as heart, lung, liver, brain, and kidney failure; 7. patients with ascites or cachexia preoperatively in poor general conditions; 8. patients diagnosed with immunodeficiency, immunosuppression, or autoimmune diseases (such as allogeneic bone marrow transplant, immunosuppressive drugs, sle, etc.). 9. patients refusing to sign the informed consent of the study;
vascular no-react graft against infection

Conditions: Vascular Infections

Summary: this study seeks to demonstrate the effectiveness and safety of the non-valved conduit for ce marking on the basis of infection. the rationale for infection resistance with the conduit is that biointegral surgical no-react® treated products have a well-documented history of infection resistance in hybrid vascular settings.


Eligibility criteria:
inclusion criteria: * infected prosthetic graft and/or bifurcation * high risk of infection at graft implantation * mycotic aneurysm * no alternative available exclusion criteria: * below-knee procedure * av access
trial comparing home-based cardiac rehabilitation with comprehensive centre-based cardiac rehabilitation in patients older than 65 years with coronary heart disease. the homebase trial

Conditions: Coronary Heart Disease

Summary: hypothesis: home-based cardiac rehabilitation is as effective as comprehensive centre-based cardiac rehabilitation in patients older than 65 years.

participation in cardiac rehabilitation is known to reduce mortality and morbidity and increase health related quality of life. however, participation rate are low among elderly cardiac patients with coronary heart disease. home-based cardiac rehabilitation could be an attractive alternative to the centre-based programmes but studies investigating the effect of these programmes are limited and even less is known about the effect among the elderly.

Eligibility criteria:
inclusion criteria: 1. event of coronary heart disease (new myocardial infarction, cabg or pci) exclusion criteria: 1. care home patients. 2. serious disability incompatible with rehabilitation. 3. social circumstances incompatible with participation.

Keywords: cardiac rehabilitation exercise heart failure coronary heart disease
usefulness of dornase in covid-19 on hfno

Conditions: COVID-19 Pneumonia

Summary: covid-19 pneumonia manifests among others with a thick bronhial secretion. it contains an increased number of neutrophil extracellular traps (nets), formed during netosis. dna is a major component in nets. dnase alfa (pulmozyme®, roche) is a recombinant human enzyme, registered for inhalations in patients with cystic fibrosis, in which nets are also a typical characteristic. dnase alfa inhalations are typically well tolerated and with no major side effects. some initial reports exist of using dnase alfa inhalations in covid-19 patients, that had benefitial effects. there are some trials registered with clinicaltrials, investigating the usufulness of dnase alfa in intubated patients, but the investigators have no knowledge of a trial, investigating the usufulness of this drug in patients receiving high flow nasal oxygen therapy.


Eligibility criteria:
inclusion criteria: * positive sars-cov-2 rna pcr swab * inflamatory phase of infection * hfno exclusion criteria: * pregnancy * previous treatment with dnase alfa
espb and acb in knee arthroplasty

Conditions: Post Operative Pain

Summary: total knee arthroplasty surgery is preferred in the treatment of osteoarthritis and causes severe postoperative pain. in this study, we aimed to investigate the effects of lumbar erector spina plan block and adductor canal block on postoperative pain and quadriceps muscle strength in patients who underwent total knee arthroplasty with spinal anesthesia.

in a prospective, randomized study; medeniyet university faculty of medicine göztepe prof. dr. forty patients who underwent total knee arthroplasty surgery at süleyman yalçın city hospital were divided into two groups. after the surgery was completed, erector spina plane block was applied to group e (n=20) patients with 20 ml of 0.25% bupivacaine from the operated side l3-l4 level, while in group a (n=20) patients, in the area where the sartorius muscle crosses the adductor magnus muscle, it was lateral to the superficial femoral artery. adductor canal block was applied to the adductor canal with 20 ml of 0.5% bupivacaine. all patients were administered 1 gr paracetamol and 75 mg diclofenac sodium when their pain started in the orthopedic ward. numerical pain score and quadriceps muscle strength were evaluated during the 48-hour follow-up of the patients. when the pain score was 4 and above, 50 mg pethidine hydrochloride was administered.

Eligibility criteria:
inclusion criteria: * patients who underwent total knee arthroplasty surgery * asa i-iii patients exclusion criteria: * patients with coagulopathy * patients history with local anesthetic allergy or toxicity * patients with long hospital stay * patients with advanced organ failure * mental retarded patients * presence of infection at the injection site

Keywords: erector spinae plane block adductor canal block total knee arthroplasty
novel internet-based interventions to reduce sexual risk among men who have sex with men

Conditions: HIV Infections

Summary: the purpose of this study is to develop and test the efficacy of online hiv risk reduction interventions among men who have sex with men.

this is an internet-based, five-branch randomized controlled intervention, enrolling 3,000 adult msm. the five branches include 1) a control condition receiving no intervention content, 2) a standard text-based prevention webpage, 3) an 8 minute dramatic video addressing sexual risk reduction within the context of alcohol use, 4) a 5 minute documentary video addressing hiv disclosure, hiv testing, and condom use with the sub-context of drug use, and 5) both videos. after completing the baseline survey, eligible participants who consent to participate in the intervention will be randomly assigned to the control condition or one of the four intervention conditions. the control condition will not include the delivery of any intervention content. all participants (branches 1-5) will be asked to complete a brief post-intervention survey (to measure intentions). all intervention participants will be invited to complete a final 60-day follow-up survey.

Eligibility criteria:
inclusion criteria: * male; * age 18 and over; * ability to read and respond in english; * reside within the united states; * report oral or anal sex with any male (new partner or not) in the past 60 days and report oral, anal or vaginal sex for the first time with any partner (male or female) in the past 60 days; * complete baseline survey * provide an email address; exclusion criteria: * women and transgender persons

Keywords: hiv internet msm condom use disclosure
a study to evaluate orally-administered oseltamivir and intravenous zanamivir in healthy subjects

Conditions: Healthy Subjects

Summary: this study is a 4 period study to see if there is any interaction between orally-administered oseltamivir and intravenous zanamivir in healthy thai adult subjects


Eligibility criteria:
inclusion criteria: * healthy volunteer(s)confirmed by physical exam, clinical labs, ecgs, and vitals * must be woman of non-childbearing potential or willing to abstain from intercourse for two weeks prior to study drug administration and throughout the study or be willing to use two acceptable methods of birth control. exclusion criteria: * subjects with history of certain heart problems or subjects with hepatitis b, c or hiv.

Keywords: zanamivir, influenza virus, healthy volunteer, pk, drug interaction, iv, and oseltamivir.
effect of antifibrotic therapy on regression of myocardial fibrosis after transcatheter aortic valve implantation (tavi) in aortic stenosis patients with high fibrotic burden

Conditions: Aortic Stenosis, Severe

Summary: the aim of the study is to evaluate the effect of antifibrotic therapy on regression of myocardial fibrosis after tavi in patients with baseline high fibrotic burden. therefore, patients will be treated with spironolactone in addition to standard of care, spioronolactone + dihydralazine in addition to standard of care or according to standard of care alone without any study medication. first, differences between patients in the control arm and patients randomized to anti-fibrotic therapy will be analyzed. the second analysis will determine, whether dihydralazine medication in addition to spironolactone is able to increase a potential antifibrotic effect. myocardial fibrosis will be assessed by cardiac magnetic resonance imaging (cmr) before tavi and 1 year after. quantification of potentially irreversible replacement fibrosis will be carried out by late gadolinium enhancement (lge), and quantification of the potentially reversible diffuse interstitial fibrosis will be performed by measurement of the extracellular volume fraction (ecv), thereby deriving matrix volume and cell volume.


Eligibility criteria:
inclusion criteria: * male, female age ≥ 60 * diagnosis of severe symptomatic aortic stenosis * transcatheter aortic valve implantation (tavi) scheduled * written informed consent exclusion criteria: * 1. pre-existing dilative or ischemic heart disease with ef\<35% and guideline indication for spironolactone * patient on current medication with spironolactone, eplerenone, or dihydralazine * presence of coexistent myocardial pathology such as cardiac amyloidosis, hypertrophic cardiomyopathy, or myocarditis * presence of coexistent severe aortic regurgitation or severe mitral stenosis * previous surgical valve replacement or repair * pacemaker or icd implanted * renal impairment (serum creatinine \> 1,8 mg/dl and/ or gfr \< 30 ml/min/1,73 m² bsa) * significant hypotension (blood pressure \< 90 mm hg systolic and/or \< 50 mm hg diastolic * serum potassium \> 5,1 mmol/l * contraindications for spironolactone (anuria, acute renal failure, serum creatinine \> 1.8 mg/dl, hyperkalemia, pregnancy) * contraindications for dihydralazine (known allergy or hypersensitivity, systemic lupus erythematodes, adrenocortical disorders) * known active malignant disease with life expectancy \< 1 year * women with child-bearing potential * simultaneous participation (including a waiting period of 4 weeks) in other interventional clinical trials * patient without legal capacity who is unable to understand the nature, significance and consequences of the trial * person who is in a relationship of dependence/employment with the sponsor or the investigator